With eight years of experience in the sector, Biolab Genéricos reinforces the concept of “branded generic”

With a solid track record in one of the industry's most competitive segments, Biolab Genéricos, from Biolab & Co. is expanding its presence in the national pharmaceutical retail market. Recognized in the market as the “branded generic”, the line carries Biolab Farmacêutica's DNA of scientific rigor, being produced in the same laboratories and under the same standards of excellence as the reference products.

“Biolab Genéricos” consistent growth is the result of a clear positioning and a value proposition that goes beyond price. We have built our credibility over decades, with a focus on quality and commitment to health. And this sets us apart in a market where trust is fundamental," says Fabio Amorosino, CEO of the Biolab & Co. Group.

The success of this trajectory, Amorosino points out, stems from the strategic combination of a strong brand, long-term vision and product safety. The result is that the unit, which is only eight years old, is already among the leading companies in the sector in the country.

The entire range carries the exclusive Maximum Quality Level (MGQ) seal, guaranteeing high-tech treatments that people can trust.

“To stand out in such a competitive market, we have invested in a consultative sales model, with a team trained to present the added value of our range.”

The proposal is not limited to price: Biolab Genéricos products offer a combination of recognized quality, accessibility to the end consumer and attractive margins for the pharmaceutical channel,” explains Guilherme Pittoli, Director of Biolab Genéricos.

Pittoli emphasizes that an important part of the brand's strength is also due to a strong partnership with distributors, large chains and independent pharmacies, which guarantees the brand's capillarity throughout the country.

“Our focus is on building sustainable relationships with all the links in the chain - from distribution to points of sale. And, above all, ensuring that the population has access to high-quality medicines at fair prices. This is our commitment and what has sustained our growth,” says the CEO of Grupo Biolab & Co.

Democratization of access

Generic Medicines Day, celebrated on May 20, is a fundamental milestone for public health in Brazil, symbolizing the democratization of access to high-quality treatments. This date celebrates a policy that, 27 years ago, transformed the country's reality by ensuring that safe and effective therapies reach those who need them most at more affordable prices. For Biolab Genéricos, the date reinforces its mission to unite efficacy and accessibility, bringing high technology to the daily care of the Brazilian population.